| As Of | Filing | | Doc. | | Page | | Title | Docs. |
|---|
| | |  |
| 7/31/23 | | PRE 14A | | | | 1 | | A-1 | 1 |
| 8/18/23 | | 424B5 | | | | 1 | | About Baudax | 1 |
| | | | | | 1 | | About Baudax Bio, Inc | 1 |
| 9/21/23 | | S-1/A | | | | 1 | | About This Prospectus | 6 |
| 8/18/23 | | 424B5 | | | | 1 | | About This Prospectus Supplement | 1 |
| 9/21/23 | | S-1/A | | | | 1 | | Alumni Capital Transaction, The | 2 |
| 9/7/23 | | DEF 14A | | | | 1 | | Annex A: Proposed Amendment to Amended and Restated Articles of Incorporation of Baudax Bio, Inc | 3 |
| | | | | | 1 | | ANNEX B: AUDITED FINANCIAL STATEMENTS AND ACCOMPANYING NOTES OF TERAIMMUNE, INC. (December 31, 2022 and December 31, 2021) | 3 |
| | | | | | 1 | | ANNEX C: UNAUDITED FINANCIAL STATEMENTS AND ACCOMPANYING NOTES OF TERAIMMUNE, INC. (Three Months Ended March 31, 2023 and 2022) | 3 |
| | | | | | 1 | | Annex D: Unaudited Pro Forma Condensed Combined Financial Statements | 3 |
| | | | | | 1 | | Annex E: Management of Terraimmune's Discussion and Analysis of Financial Condition and Results of Operations | 3 |
| 7/31/23 | | PRE 14A | | | | 1 | | B- 1 | 1 |
| | | | | | 1 | | B-3 | 1 |
| | | | | | 1 | | B-4 | 1 |
| | | | | | 1 | | B-5 | 1 |
| | | | | | 1 | | B-6 | 1 |
| | | | | | 1 | | B-7 | 1 |
| | | | | | 1 | | B-8 | 1 |
| 9/7/23 | | DEF 14A | | | | 1 | | Background and Reasons for the Transactions | 3 |
| | | | | | 1 | | Baudax Management Following the Acquisition | 3 |
| 7/31/23 | | PRE 14A | | | | 1 | | C- 1 | 1 |
| | | | | | 1 | | C-17 | 1 |
| | | | | | 1 | | C-4 | 1 |
| | | | | | 1 | | C-5 | 1 |
| | | | | | 1 | | C-6 | 1 |
| | | | | | 1 | | C-7 | 1 |
| | | | | | 1 | | C-8 | 1 |
| 9/7/23 | | DEF 14A | | | | 1 | | Cautionary Information Regarding Forward-Looking Statements | 3 |
| 9/21/23 | | S-1/A | | | | 1 | | Cautionary Note Regarding Forward-Looking Statements | 8 |
| 4/28/23 | | 424B3 | | | | 1 | | Certain Relationships and Related Transactions | 3 |
| 9/7/23 | | DEF 14A | | | | 1 | | Change in Independent Registered Public Accounting Firm | 3 |
| | | | | | 1 | | Consolidated Balance Sheets as of December 31, 2022 and 2021 | 3 |
| 11/22/23 | | 424B3 | | | | 1 | | Consolidated Financial Statements (Unaudited) | 4 |
| 9/7/23 | | DEF 14A | | | | 1 | | Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021 | 3 |
| | | | | | 1 | | Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021 | 3 |
| | | | | | 1 | | Consolidated Statements of Stockholders' Equity (Deficit) for the Years Ended December 31, 2022 and 2021 | 3 |
| 11/22/23 | | 424B3 | | | | 1 | | Controls and Procedures | 4 |
| 7/31/23 | | PRE 14A | | | | 1 | | D-1 | 1 |
| 11/22/23 | | 424B3 | | | | 1 | | Defaults Upon Senior Securities | 4 |
| 9/7/23 | | DEF 14A | | | | 1 | | Description of Business of Baudax Bio, Inc | 3 |
| 9/21/23 | | S-3/A | | | | 1 | | Description of Capital Stock | 6 |
| 9/7/23 | | DEF 14A | | | | 1 | | Description of Common Stock | 3 |
| 8/18/23 | | 424B5 | | | | 1 | | Description of Debt Securities | 1 |
| 9/21/23 | | S-1/A | | | | 1 | | Description of Our Securities | 2 |
| 8/18/23 | | 424B5 | | | | 1 | | Description of Our Subscription Rights | 1 |
| | | | | | 1 | | Description of Our Units | 1 |
| | | | | | 1 | | Description of Our Warrants | 1 |
| | | | | | 1 | | Description of Securities We Are Offering | 4 |
| 9/7/23 | | DEF 14A | | | | 1 | | Description of the Transactions | 3 |
| 8/18/23 | | 424B5 | | | | 1 | | Description of Units | 1 |
| | | | | | 1 | | Description of Warrants | 1 |
| | | | | | 1 | | Dilution | 4 |
| 4/28/23 | | 424B3 | | | | 1 | | Director Compensation | 3 |
| 9/21/23 | | S-1/A | | | | 1 | | Dividend Policy | 6 |
| 7/31/23 | | PRE 14A | | | | 1 | | E- 1 | 1 |
| 4/28/23 | | 424B3 | | | | 1 | | Executive Officer Compensation | 3 |
| 11/22/23 | | 424B3 | | | | 1 | | Exhibits | 4 |
| 9/21/23 | | S-1/A | | | | 1 | | Experts | 8 |
| 11/22/23 | | 424B3 | | | | 1 | | Forward-Looking Statements | 4 |
| 8/18/23 | | 424B5 | | | | 1 | | Global Securities | 1 |
| 9/7/23 | | DEF 14A | | | | 1 | | Householding | 3 |
| 8/18/23 | | 424B5 | | | | 1 | | Incorporation by Reference | 1 |
| 9/21/23 | | S-1/A | | | | 1 | | Incorporation of Certain Information by Reference | 6 |
| 9/21/23 | | S-3/A | | | | 1 | | Incorporation of Documents by Reference | 2 |
| 9/7/23 | | DEF 14A | | | | 1 | | Independent Registered Public Accounting Firm Fees | 3 |
| | | | | | 1 | | Information Concerning Solicitation and Voting | 3 |
| 9/21/23 | | S-1/A | | | | 1 | | Legal Matters | 8 |
| 11/22/23 | | 424B3 | | | | 1 | | Legal Proceedings | 4 |
| | | | | | 1 | | Management's Discussion and Analysis of Financial Condition and Results of Operations | 4 |
| 9/7/23 | | DEF 14A | | | | 1 | | Material Contracts Entered Into and Assumed in the Acquisition | 3 |
| 11/22/23 | | 424B3 | | | | 1 | | Mine Safety Disclosures | 4 |
| 9/7/23 | | DEF 14A | | | | 1 | | Notes to Consolidated Financial Statements | 3 |
| 7/31/23 | | PRE 14A | | | | 1 | | Notes to Unaudited Condensed Consolidated Financial Statements | 1 |
| 9/21/23 | | S-1/A | | | | 1 | | Offering, The | 8 |
| 11/22/23 | | 424B3 | | | | 1 | | Other Information | 7 |
| 9/7/23 | | DEF 14A | | | | 1 | | Other Matters | 3 |
| | | | | | 1 | | Overview | 3 |
| 11/22/23 | | 424B3 | | | | 1 | | Part I. Financial Information | 4 |
| | | | | | 1 | | Part Ii. Other Information | 4 |
| 9/21/23 | | S-1/A | | | | 1 | | Plan of Distribution | 8 |
| 9/5/23 | | S-1 | | | | 1 | | Power of Attorney | 4 |
| 9/7/23 | | DEF 14A | | | | 1 | | Principal Shareholders | 3 |
| 8/18/23 | | 424B5 | | | | 1 | | Private Placement Transaction | 1 |
| 9/7/23 | | DEF 14A | | | | 1 | | Proposal No. 1: Approval of Conversion Proposal | 3 |
| | | | | | 1 | | Proposal No. 2 Approval of the Amendment to the Amended and Restated Certificate of Incorporation to Effect the Reverse Stock Split | 3 |
| | | | | | 1 | | Proposal No. 3. Approval of Eloc Issuance Proposal | 2 |
| 7/31/23 | | PRE 14A | | | | 1 | | Proposal No. 3: Ratification of Appointment of Eisneramper as Our Independent Registered Public Accounting Firm for 2023 | 1 |
| 9/7/23 | | DEF 14A | | | | 1 | | Proposal No. 4. Approval of Warrant Exercise Proposal | 2 |
| 7/31/23 | | PRE 14A | | | | 1 | | Proposal No. 4: Approval of Adjournment of the Special Meeting | 1 |
| 9/7/23 | | DEF 14A | | | | 1 | | Proposal No. 5: Ratification of Appointment of Eisneramper as Our Independent Registered Public Accounting Firm for 2023 | 2 |
| | | | | | 1 | | Proposal No. 6: Approval of Adjournment of the Special Meeting | 2 |
| | | | | | 1 | | Proposals | 3 |
| 9/21/23 | | S-1/A | | | | 1 | | Prospectus Summary | 5 |
| 8/18/23 | | 424B5 | | | | 1 | | Prospectus Supplement Summary | 1 |
| 11/22/23 | | 424B3 | | | | 1 | | Quantitative and Qualitative Disclosures About Market Risk | 4 |
| 9/7/23 | | DEF 14A | | | | 1 | | Questions and Answers About the Special Meeting | 3 |
| | | | | | 1 | | Reports of Independent Registered Public Accounting Firm | 3 |
| | | | | | 1 | | Risk Factor Summary | 3 |
| 11/22/23 | | 424B3 | | | | 1 | | Risk Factors | 15 |
| 4/28/23 | | 424B3 | | | | 1 | | Security Ownership of Certain Beneficial Owners and Management | 3 |
| 9/21/23 | | S-1/A | | | | 1 | | Selling Shareholder | 2 |
| 9/21/23 | | S-3/A | | | | 1 | | Selling Shareholder, The | 2 |
| 11/22/23 | | 424B3 | | | | 1 | | Signatures | 4 |
| 8/18/23 | | 424B5 | | | | 1 | | Special Note Regarding Forward-Looking Statements | 1 |
| 9/21/23 | | S-3/A | | | | 1 | | Summary | 2 |
| 9/21/23 | | S-1/A | | | | 1 | | Table of Contents | 11 |
| | | | | | 1 | | The Alumni Capital Transaction | 2 |
| | | | | | 1 | | The Offering | 8 |
| 9/21/23 | | S-3/A | | | | 1 | | The Selling Shareholder | 2 |
| 7/31/23 | | PRE 14A | | | | 1 | | Unaudited Condensed Consolidated Balance Sheets as at March 31, 2023 and December 31, 2022 | 1 |
| | | | | | 1 | | Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 | 1 |
| | | | | | 1 | | Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 | 1 |
| | | | | | 1 | | Unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three months ended March 31, 2023 and 2022 | 1 |
| 11/22/23 | | 424B3 | | | | 1 | | Unregistered Sales of Equity Securities and Use of Proceeds | 4 |
| 9/21/23 | | S-1/A | | | | 1 | | Use of Proceeds | 8 |
| 9/7/23 | | DEF 14A | | | | 1 | | Websites | 3 |
| | | | | | 1 | | Where You Can Find Additional Information | 3 |
| 9/21/23 | | S-1/A | | | | 1 | | Where You Can Find More Information | 8 |
